6th Digital Pharma & Life Sciences Conference 2011

22 February 2011, Wiesbaden, Germany.
For the sixth time Microsoft and its partners will be holding the Digital Pharma & Life Sciences conference. The lecture event and exhibition is aimed at the pharmaceutical, chemical and life sciences industries, showing current projects and innovative technologies that support greater sustainability, cost efficiency and competitiveness in and through IT.

IT has become a critical competitive factor as an instrument for sustainable climate and environmental protection. The framework is set by international initiatives by industries and governments: for example more than 500 investors request global listed companies to report their CO2 relevant business data through the Carbon Disclosure Project (CDP) from the UK. Global initiatives for Green Chemistry such as the conventions from Stockholm, Rotterdam and Basel, the OECD and the regulatory authorities of developed countries are working to create global standards for sustainable risk and chemicals management.

For this reason, the Digital Pharma & Life Sciences conference 2011 is focussing on the topics "Green IT – Green Chemistry". With the focus on "Green in IT", experts will discuss latest developments of Green IT technologies on the basis of recent successful projects in order to make processes more efficient, save resources and energy and thereby reduce costs. These include concepts for IT virtualization in controlling chemical production or cloud computing for pharmaceutical research.

The "Green through IT" presentations will show pioneering Green Chemistry projects that ensure sustainability in production, research and development and overall global supply chains. Leading companies from the chemical, pharmaceutical and life sciences industries demonstrate how they coordinate production and logistics processes better through intelligent technologies, plan forward-looking and therefore design initiatives for more economically measurable sustainability.

The conference takes place on 22nd February 2011 in the Kurhaus Wiesbaden and is aimed at decision makers and experts from the fields of IT and business management, research and development, business development management, product management, production, quality management, sales and controlling.

During the accompanying exhibition, the partners of the Digital Pharma & Life Sciences initiative will show latest IT technologies and reference projects. On the eve of the conference on 21st February 2011, an exclusive dinner will take place with all the speakers, conference participants and partners of the initiative.

Further information for registration, the agenda and logistic details are available at:
http://www.digitalpharma.de

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...